Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literature

Abstract

Introduction

The data on the use of dual biologics are scant, but a topic of current interest.

Case Study

In this report, the treatment regimen of a patient with two T helper 2 pathway-related comorbidities, severe asthma, and chronic spontaneous urticaria, was presented.

Results

Both urticaria and asthma symptoms of the patient could not be controlled entirely with monotherapy while both diseases could be controlled after omalizumab-mepolizumab dual treatment. No adverse events were observed after 6 months of dual biologics use.

Conclusion

This report supports other publications in the literature involving the use of dual biologics and provides a summary of the literature.

Keywords:

• Severe asthma
• chronic spontaneous urticarial
• omalizumab
• mepolizumab
• dual biologics

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.